M.E.D.U.S.A. Scalper Indicator

The former Goldman Sachs VP -- who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio -- is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Have a look at our curated list of today's top market news, and some special offers from our valued partners.

"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." - Ad The former Goldman Sachs VP -- who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio -- is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio." Continue reading ➔ Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update As the demand for obesity drugs continues to surge, biopharma companies are eagerly seizing the opportunity to capitalize on the trend. Continue reading ➔ The Next 5 Minutes Could Change Your Life Forever - Ad Just days ago our top trading expert, Jim Fink, took part in an explosive interview where he proved beyond a shadow of a doubt how his powerful system multiplies the small stock market gains most investors accept into massive triple-digit profits. Continue reading ➔ Shell Exits Chinese Power Market, Eyes Gas Growth: Report Shell reportedly exits China's power markets, focusing on bolstering profitability in natural gas and oil sectors. The move reflects a commitment to invest selectively in profitable ventures within the power sector, aligning with CEO Wael Sawan's vision. Continue reading ➔ Why MiNK Therapeutics Stock Is Up 11% Monday MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. Continue reading ➔ Elon's New A.I. Device is About to Shock the World - Ad Using this device you see... Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in... "The next step in human evolution." See the details. Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly. Continue reading ➔ Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues Rapidly climbing sales of the and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. Continue reading ➔ This under-the-radar company is primed for an incredible year! - Ad Every week we reveal diamonds in the rough, under-the-radar stocks so make sure you don't miss out! Text STOCKS to (833) 861-1388. Continue reading ➔ Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (May 5-May 11, 2024) EPAM, SHOP, RBLX, BLDR, PLTR, ALAB, SUZ, VIV, ABNB, DIS were worst performers last week. Analysts revised price targets for these stocks. Continue reading ➔ Campaign to build new California city submits signatures to get on November ballot SAN FRANCISCO (AP) — A wealthy Silicon Valley-backed campaign to build a green city for up to 400,000 people in the San Francisco Bay Area has submitted what it says are enough signatures to qualify the initiative for the November election. Continue reading ➔ What's the Big Thing Musk, Bezos and Tim Cook All Have in Common? - Ad One of America's most controversial CEOs says, "A new form of money in America is making some people (including Elon Musk, Jeff Bezos, and 17 of America's 25 wealthiest individuals), rich. It has nothing to do with gold, bitcoin, or anything like that, but it's 100% legal. The problem? Few Americans have a real understanding of how it works. CEO explains here. Trump Meets With DeSantis, Noem Stirs Up Controversy: How Will Republican Vice President Betting Odds Be Impacted? The relationship between Donald Trump and Ron DeSantis was heated at times during the Republican primary season, before the Florida governor dropped out of the 2024 presidential election and threw his support behind the Continue reading ➔ How Does The Semiconductor Index Trend Compare To Nasdaq? Analyst Opines Last week, the SOX was up 2% while the NASDAQ and S&P were up 1% and 2%. U.S. is cracking down on Huawei, impacting Intel and Qualcomm's revenue. Continue reading ➔ Deadline for businesses to apply for their share of massive credit card company settlement looms NEW YORK (AP) — A deadline is looming for millions of businesses who may be entitled to a payout in . Continue reading ➔ The Magnificent Seven: Here's How You Can Profit From Their Dividend Programs The Magnificent Seven issue dividends to shareholders, despite being considered growth stocks. Continue reading ➔ What's Going On With Rivian's Stock? Rivian reported better-than-expected first-quarter revenue last week, and the company also maintained its 2024 production forecast of 57,000 units. Rivian shares also moved following a report from DigiTimes that Apple is "assessing the possibility of teaming up with a certain U.S. EV startup, and Rivian is a very likely candidate." Continue reading ➔ Why Is Apple Stock Soaring Premarket Today? Apple shares appear on track to reclaim the $180 level for the first time since the start of March after quarterly earnings. Continue reading ➔

Information, charts or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising as well as partner offers for which we may receive affiliate compensation. We only send these offers to those who have opted in to our newsletter. If you wish to no longer receive these offers click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault. 339-20 De Boers Dr., Toronto, ON M3J 0H1, 917.672.7040 © 2024 Musth | FinStrategist | All rights reserved. Unsubscribe